• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Fortrea Holdings Inc.

    3/11/26 5:16:27 PM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email

    Unavailable

    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    3/9/2026$15.00Hold → Buy
    TD Cowen
    1/8/2026$22.00Hold → Buy
    Truist
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea to Attend Jefferies Global Healthcare Conference

    DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization ("CRO"), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference: Jefferies Global Healthcare Conference (NYC)Date: Thursday, June 4, 2026Time: 8:45 AM EDTFormat: Fireside Chat To register for the live webcast, please click here. A replay will be available in the Events & Presentations section of Fortrea's Investor Relations website. Investors interested in one-on-one or group meetings should contact their Jefferies representatives. About Fortrea Fortrea (NASDAQ:FTRE) is

    6/2/26 6:00:55 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports First Quarter 2026 Results

    Strong first-quarter performance reinforces confidence in FY 2026 guidanceBook-to-bill of 1.15x is third consecutive quarter above 1.1x Highlights For the three months ended March 31, 2026: Revenues of $636.5 millionBook-to-bill ratio of 1.15x, resulting in 1.05x book-to-bill for the trailing 12 monthsGAAP net loss of $(23.6) million, or $(0.25) per diluted shareAdjusted EBITDA of $47.0 millionAdjusted net income of $15.2 million, or $0.16 per diluted shareFull-year guidance affirmed DURHAM, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the first quarter ended M

    5/5/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call

    DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webcast c

    4/21/26 8:45:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by TD Cowen with a new price target

    TD Cowen upgraded Fortrea from Hold to Buy and set a new price target of $15.00

    3/9/26 8:42:40 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    SEC Filings

    View All

    SEC Form 144 filed by Fortrea Holdings Inc.

    144 - Fortrea Holdings Inc. (0001965040) (Subject)

    5/18/26 4:24:09 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Fortrea Holdings Inc.

    10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

    5/5/26 4:06:46 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    5/5/26 6:12:19 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Morais Mark A. converted options into 11,006 shares and sold $75,374 worth of shares (4,866 units at $15.49), increasing direct ownership by 9% to 76,039 units (SEC Form 4) (tax withholding)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/3/26 4:08:56 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Financial Officer Mcconnell Jill G. converted options into 11,006 shares and sold $75,374 worth of shares (4,866 units at $15.49), increasing direct ownership by 8% to 78,416 units (SEC Form 4) (withholding obligation)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/3/26 4:06:27 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Accounting Officer Parks Robert sold $26,880 worth of shares (2,000 units at $13.44), decreasing direct ownership by 9% to 20,389 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    5/20/26 4:09:53 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Reports First Quarter 2026 Results

    Strong first-quarter performance reinforces confidence in FY 2026 guidanceBook-to-bill of 1.15x is third consecutive quarter above 1.1x Highlights For the three months ended March 31, 2026: Revenues of $636.5 millionBook-to-bill ratio of 1.15x, resulting in 1.05x book-to-bill for the trailing 12 monthsGAAP net loss of $(23.6) million, or $(0.25) per diluted shareAdjusted EBITDA of $47.0 millionAdjusted net income of $15.2 million, or $0.16 per diluted shareFull-year guidance affirmed DURHAM, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the first quarter ended M

    5/5/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call

    DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webcast c

    4/21/26 8:45:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care